Scientific publications

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Sep 26, 2019 | Magazine: Leukemia

Wang M (1), Rule S (2), Zinzani PL (3), Goy A (4), Casasnovas O (5), Smith SD (6), Damaj G (7), Doorduijn JK (8), Lamy T (9), Morschhauser F (10), Panizo C (11), Shah B (12), Davies A (13), Eek R (14), Dupuis J (15), Jacobsen E 16, Kater AP (17), Le Gouill S (18), Oberic L (19), Robak T (20), Jain P (21), Frigault MM (22), Izumi R (22), Nguyen D (22), Patel P (22), Yin M (22), Długosz-Danecka M (2)3.

(1) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
(2) Plymouth University Medical School, Plymouth, UK.
(3) Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
(4) John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
(5) CHU Dijon - Hôpital d'Enfants, Dijon, France.
(6) Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
(7) Institut d'Hématologie de Basse-Normandie, Caen, France.
(8) Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands.
(9) CHU de Rennes, Rennes, France.
(10) Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000, Lille, France.
(11) Clínica Universidad de Navarra, Pamplona, Spain.
(1)2 Moffitt Cancer Center, Tampa, FL, USA.
(13) Cancer Research UK Centre, University of Southampton Faculty of Medicine, Southampton, UK.
(14) Border Medical Oncology, Albury, Victoria, Australia.
(15) Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France.
(16) Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
(17) Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, HOVON Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands.
(18) CHU de Nantes-Hotel Dieu, Nantes, France.
(19) Institut Universitaire du Cancer-Oncopole Toulouse (IUCT-O), Toulouse, France.
(20) Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
(21) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
(22) Acerta Pharma, South San Francisco, CA, USA.
(23) Department of Haematology, Jagiellonian University, Krakow, Poland.

Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1,2,3,4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up.

CITATION  Leukemia. 2019 Sep 26. doi: 10.1038/s41375-019-0575-9. 

Our authors

Navarre headquarters
Madrid headquarters